[go: up one dir, main page]

ATE128964T1 - Anwendung von beta-alethin in zellkultur und therapie. - Google Patents

Anwendung von beta-alethin in zellkultur und therapie.

Info

Publication number
ATE128964T1
ATE128964T1 AT91912761T AT91912761T ATE128964T1 AT E128964 T1 ATE128964 T1 AT E128964T1 AT 91912761 T AT91912761 T AT 91912761T AT 91912761 T AT91912761 T AT 91912761T AT E128964 T1 ATE128964 T1 AT E128964T1
Authority
AT
Austria
Prior art keywords
alethine
beta
therapy
application
cell culture
Prior art date
Application number
AT91912761T
Other languages
English (en)
Inventor
Galen Daryl Knight
Paul Leslie Mann
Terence Joseph Scallen
Original Assignee
Univ New Mexico
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New Mexico filed Critical Univ New Mexico
Application granted granted Critical
Publication of ATE128964T1 publication Critical patent/ATE128964T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0093—Purging against cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
AT91912761T 1990-07-06 1991-07-08 Anwendung von beta-alethin in zellkultur und therapie. ATE128964T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54910390A 1990-07-06 1990-07-06
US54910490A 1990-07-06 1990-07-06

Publications (1)

Publication Number Publication Date
ATE128964T1 true ATE128964T1 (de) 1995-10-15

Family

ID=27069009

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91912761T ATE128964T1 (de) 1990-07-06 1991-07-08 Anwendung von beta-alethin in zellkultur und therapie.

Country Status (9)

Country Link
EP (1) EP0538330B1 (de)
JP (1) JP3319597B2 (de)
AT (1) ATE128964T1 (de)
AU (1) AU646875B2 (de)
DE (1) DE69113802T2 (de)
DK (1) DK0538330T3 (de)
ES (1) ES2080954T3 (de)
GR (1) GR3018632T3 (de)
WO (1) WO1992000960A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69131752T2 (de) * 1990-07-06 2000-06-29 University Of New Mexico, Albuquerque Vitalethin und seine anwendung in zellkultur und therapie
US6245561B1 (en) 1990-07-06 2001-06-12 University Of New Mexico β-alethine use in cell culture and therapy
US5643966A (en) * 1990-07-06 1997-07-01 University Of New Mexico β-alethine as anti-tumor agent
AU4372393A (en) * 1993-05-12 1994-12-12 Oculon Corporation Chemical prevention or reversal of cataract by phase separation inhibitors
EP1018877A4 (de) * 1995-10-17 2000-08-09 Dovetail Technologies Inc Zell-, knochenmark- und immunistimulanzen mit niedrigerm molekulargewicht
WO1999042097A1 (en) 1998-02-24 1999-08-26 Dovetail Technologies Inc. Small molecules that elicit a polarized th1 response and for modulation of cellular immunity
US6762174B1 (en) 1998-02-24 2004-07-13 Dovetail Technologies, Inc. Low molecular weight compounds administered together with anti-cancer agents to prevent or treat cancer and pharmaceutical compositions thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552765A (en) * 1982-05-14 1985-11-12 Santen Pharmaceutical Co., Ltd. Aletheine derivatives

Also Published As

Publication number Publication date
AU8207791A (en) 1992-02-04
AU646875B2 (en) 1994-03-10
GR3018632T3 (en) 1996-04-30
EP0538330A4 (en) 1993-07-07
EP0538330B1 (de) 1995-10-11
DE69113802D1 (de) 1995-11-16
JP3319597B2 (ja) 2002-09-03
ES2080954T3 (es) 1996-02-16
EP0538330A1 (de) 1993-04-28
DE69113802T2 (de) 1996-05-15
WO1992000960A1 (en) 1992-01-23
JPH05508769A (ja) 1993-12-09
DK0538330T3 (da) 1996-02-26

Similar Documents

Publication Publication Date Title
DE3860043D1 (de) Verwendung von biertreberextrakt zur herstellung von medizinischen und kosmetischen zubereitungen.
BR9910251A (pt) Estimulação hematopoiética
BG60253B1 (bg) Човешки тъканен плазминогенен активатор
ATE87214T1 (de) Verwendung katabolischer enzyme zur herstellung eines medikaments zum bekaempfen der erworbenen immunschwaeche (aids) und deren vorstadien (las, arc).
ES8103162A1 (es) Un procedimiento para la preparacion de interferon tipo ii.
DE3888064D1 (de) Niederfrequenz-Elektrotherapiegerät.
AU6649996A (en) Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
ATE81984T1 (de) Verwendung von granulozyt-makrophagen-kolonie erregenden faktor zur herstellung eines medikaments zur behandlung von bakterieller krankheiten.
ATE81776T1 (de) Verwendung von chinolon und naphthyridinantibiotika zur herstellung von ophthalmischen arzneimitteln.
ATE311191T1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
FI953565A7 (fi) Uusi antikoagulanttikofaktoriaktiivisuus
ATE172117T1 (de) Verwendung von trospiumchlorid zur herstellung eines arzneimittels zur behandlung von blasenkrankheiten
ATE128964T1 (de) Anwendung von beta-alethin in zellkultur und therapie.
DE3850154D1 (de) Verwendung von Gepiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung atypischer Depression.
ITRM970238A0 (it) Uso del nerve growth factor nella conservazione di cornee in coltura, nella produzione di tessuti corneali e congiuntivali in vitro e nella terapia di patologie corneali e congiuntivali
ES2107414T3 (es) Utilizacion de interferon-beta humano para la estimulacion de la eritropoyesis.
ATE174798T1 (de) Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation
ES2068714T3 (es) Derivados de pirimidina para aumentar la actividad antitumoral.
NO162557C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive (pyrrol-1-yl)-fenyldihydropyridazinoner.
SE8102161L (sv) "3,7,11,15-tetrametyl-2,4,6,10,14-hexadekapentaensyra
HUT63441A (en) Megakariocyte colony stimultating factor protein
ATE141510T1 (de) Arzneimittel enthaltend cd14
EP0248217A3 (en) Treatment of tumors with autologous lak cells, interleukin-2 and an ornithine decarboxylase inhibitor
ES2149347T3 (es) Composiciones farmaceuticas de verotoxinas y tratamientos medicos con las mismas.
RU94024337A (ru) Антиметастатическое средство

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee